The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma. Sep 2011 - Curr. Top. Microbiol. Immunol.; 351:0070-217X [PMID:21681685] [Oosterhoff D] [Sluijter BJ] [Hangalapura BN] [de Gruijl TD]
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Sep 2011 - Clin. Cancer Res.; 17(17):1078-0432 [PMID:21771874] [Lesterhuis WJ] [de Vries IJ] [Schreibelt G] [Lambeck AJ] [Aarntzen EH] [Jacobs JF] [Scharenborg NM] [van de Rakt MW] [de Boer AJ] [Croockewit S] [van Rossum MM] [Mus R] [Oyen WJ] [Boerman OC] [Lucas S] [Adema GJ] [Punt CJ] [Figdor CG]
Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Feb 2011 - :1476-5462 [PMID:21307889] [Steele JC] [Rao A] [Marsden JR] [Armstrong CJ] [Berhane S] [Billingham LJ] [Graham N] [Roberts C] [Ryan G] [Uppal H] [Walker C] [Young LS] [Steven NM]
Changes in peripheral blood level of regulatory T cells in malignant melanoma patients during treatment with dendritic cell vaccination and low dose IL-2. Jan 2011 - :1365-3083 [PMID:21204893] [Bjoern J] [Brimnes MK] [Andersen MH] [Thor Straten P] [Svane IM]
New approaches to the development of adenoviral dendritic cell vaccines in melanoma. Dez 2010 - Curr Opin Investig Drugs; 11(12):2040-3429 [PMID:21154122] [Butterfield LH] [Vujanovic L]
Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Nov 2010 - Cancer Immunol. Immunother.:1432-0851 [PMID:21069321] [Lesterhuis WJ] [Schreibelt G] [Scharenborg NM] [Brouwer HM] [Gerritsen MJ] [Croockewit S] [Coulie PG] [Torensma R] [Adema GJ] [Figdor CG] [de Vries IJ] [Punt CJ]
Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival. Okt 2010 - :1432-0851 [PMID:20960187] [Cornforth AN] [Fowler AW] [Carbonell DJ] [Dillman RO]
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment, a phase I/II study in metastatic melanoma patients. Aug 2010 - :1078-0432 [PMID:20736326] [Jacobs JF] [Punt CJ] [Lesterhuis WJ] [Sutmuller RP] [Brouwer HM] [Scharenborg NM] [Klasen IS] [Hilbrands LB] [Figdor CG] [de Vries IJ] [Adema GJ]
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Apr 2010 - :1477-2566 [PMID:20429791] [Trepiakas R] [Berntsen A] [Hadrup SR] [Bjørn J] [Geertsen PF] [Straten PT] [Andersen MH] [Pedersen AE] [Soleimani A] [Lorentzen T] [Johansen JS] [Svane IM]
The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. ( Patients with advanced melanoma usually do not benefit from conventional chemotherapy treatment. There is therefore a true need for a new kind of therapy for melanoma. One factor responsible for the poor prognosis of melanoma is the inhibitor of apoptosis protein (IAP) family member Livin. In this) Dez 2009 - J. Virol.; 84(1):1098-5514 [PMID:19864394] [Lazar I] [Yaacov B] [Shiloach T] [Eliahoo E] [Kadouri L] [Lotem M] [Perlman R] [Zakay-Rones Z] [Panet A] [Ben-Yehuda D]
Mechanisms of murine dendritic cell antitumor dysfunction in aging. Okt 2009 - Cancer Immunol. Immunother.; 58(12):1432-0851 [PMID:19082999] [Grolleau-Julius A] [Abernathy L] [Harning E] [Yung RL]
Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy. Aug 2009 - J. Clin. Immunol.; 29(5):1573-2592 [PMID:19421847] [Cornforth AN] [Lee GJ] [Fowler AW] [Carbonell DJ] [Dillman RO]
Genetically engineered Newcastle disease virus for malignant melanoma therapy. Jun 2009 - Gene Ther.; 16(6):1476-5462 [PMID:19242529] [Zamarin D] [Vigil A] [Kelly K] [García-Sastre A] [Fong Y]
Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Mai 2009 - Prostate; 69(9):1097-0045 [PMID:19267351] [Kim S] [Lee JB] [Lee GK] [Chang J]
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Mai 2009 - Clin. Cancer Res.; 15(10):1078-0432 [PMID:19417017] [Bonehill A] [Van Nuffel AM] [Corthals J] [Tuyaerts S] [Heirman C] [François V] [Colau D] [van der Bruggen P] [Neyns B] [Thielemans K]
